Therapeutic efficacy of tumor-targeted IL2 in LTα-/- mice depends on conditioned T cells

Cancer Immunology, Immunotherapy

Volumn 55, Issue 7, 2006, Pages 861-866

  Schrama, David ^a   Voigt, Heike ^a   Eggert, Andreas O ^a   Xiang, Rong ^b   Reisfeld, Ralph A ^b   Becker, Jürgen C ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Clonal expansion; Cytokines; LT knock out; Tumor immunology

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; EXPERIMENTAL NEOPLASM; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; KNOCKOUT MOUSE; LUNG METASTASIS; LYMPHOCYTE TRANSFER; MELANOMA; MOUSE; MOUSE STRAIN; NONHUMAN; PRIMED LYMPHOCYTE TYPING; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOTOXIN-ALPHA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; SUBCUTANEOUS TISSUE; T-LYMPHOCYTE SUBSETS;

EID: 33645319177     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0076-8     Document Type: Article

References (24)

1. Abe K, Yarovinsky FO, Murakami T, Shakhov AN, Tumanov AV, Ito D, Drutskaya LN, Pfeffer K, Kuprash DV, Komschlies KL, Nedospasov SA (2003) Distinct contributions of TNF and LT cytokines to the development of dendritic cells in vitro and their recruitment in vivo. Blood 101: 1477-1483
2. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296-306
3. Banks TA, Rouse BT, Kerley MK, Blair PJ, Godfrey VL, Kuklin NA, Bouley DM, Thomas J, Kanangat S, Mucenski ML (1995) Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. J Immunol 155:1685-1693
4. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA (1996) T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183:2361-2366
5. Caux C, Vanbervliet B, Massacrier C, Ait-Yahia S, Vaure C, Chemin K, Dieu-Nosjean M, Vicari A (2002) Regulation of dendritic cell recruitment by chemokines. Transplantation 73:S7-S11
6. Cupedo T, Mebius RE (2005) Cellular interactions in lymph node development. J Immunol 174:21-25
7. De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Mariathasan S, Smith SC, Carlson R, Shornick LP, Strauss-Schoenberger J (1994) Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264:703-707
8. Eggert AO, Becker JC, Ammon M, McLellan AD, Renner G, Merkel A, Brocker EB, Kampgen E (2002) Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur J Immunol 32:122-127
9. Gillies SD, Young D, Lo KM, Foley SF, Reisfeld RA (1991) Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 10:347-356
10. Gillies SD, Young D, Lo KM, Roberts S (1993) Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem 4:230-235
11. Haraguchi M, Yamashiro S, Yamamoto A, Furukawa K, Takamiya K, Lloyd KO, Shiku H (1994) Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8- sialyl-transferase cDNA using anti-GD2 monoclonal antibody. Proc Natl Acad Sci USA 91:10455-10459
12. Heuser C, Ganser M, Hombach A, Brand H, Denton G, Hanisch FG, Abken H (2003) An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells. Br J Cancer 89:1130-1139
13. Iizuka K, Chaplin DD, Wang Y, Wu Q, Pegg LE, Yokoyama WM, Fu YX (1999) Requirement for membrane lymphotoxin in natural killer cell development. Proc Natl Acad Sci USA 96:6336-6340
14. Lode HN, Xiang R, Pertl U, Forster E, Schoenberger SP, Gillies SD, Reisfeld RA (2000) Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. J Clin Invest 105:1623-1630
15. Lund FE, Partida-Sanchez S, Lee BO, Kusser KL, Hartson L, Hogan RJ, Woodland DL, Randall TD (2002) Lymphotoxin-alpha-deficient mice make delayed, but effective, T and B cell responses to influenza. J Immunol 169:5236-5243
16. Matsumoto M, Iwamasa K, Rennert PD, Yamada T, Suzuki R, Matsushima A, Okabe M, Fujita S, Yokoyama M (1999) Involvement of distinct cellular compartments in the abnormal lymphoid organogenesis in lymphotoxin-alpha- deficient mice and alymphoplasia (aly) mice defined by the chimeric analysis. J Immunol 163:1584-1591
17. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM (1993) Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Immunol Lett 39:91-99
18. Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper MD, Browning JL, Sedgwick JD, Cyster JG (1999) Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 189:403-412
19. Schmandt R, Hill M, Amendola A, Mills GB, Hogg D (1994) IL-2-induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression. J Immunol 152:96-105
20. Schrama D, thor Straten P, Fischer WH, McLellan AD, Bröcker EB, Reisfeld RA, Becker JC (2001) Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14:111-121
21. Schrama D, Xiang R, Eggert AO, Andersen MH, Pedersen Ls LO, Kampgen E, Schumacher TN, Reisfeld RR, Becker JC (2004) Shift from systemic to site-specific memory by tumor-targeted IL-2. J Immunol 172:5843-5850
22. Suresh M, Lanier G, Large MK, Whitmire JK, Altman JD, Ruddle NH, Ahmed R (2002) Role of lymphotoxin alpha in T-cell responses during an acute viral infection. J Virol 76:3943-3951
23. Thor Straten P, Guldberg P, Seremet T, Reisfeld RA, Zeuthen J, Becker JC (1998) Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci USA 95:8785-8790
24. Wu Q, Wang Y, Wang J, Hedgeman EO, Browning JL, Fu YX (1999) The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues. J Exp Med 190:629-638